# Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)

> **NCT06977893** · PHASE3 · RECRUITING · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 194 (estimated)

## Conditions studied

- HR+/HER2- Breast Cancer

## Interventions

- **DRUG:** Neoadjuvant Chemotherapy in Combination with Toripalimab
- **DRUG:** Neoadjuvant Chemotherapy

## Key facts

- **NCT ID:** NCT06977893
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-24
- **Primary completion:** 2027-03-23
- **Final completion:** 2030-03-23
- **Target enrollment:** 194 (ESTIMATED)
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06977893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06977893, "Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06977893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*